|
... 28 in Mason Circuit Court. McGraw seeks to stop Eli Lilly's deceptive practices, collect damages, and create a fund for those who will develop diabetes and other diseases from taking McGraw's complaint states that the Food and Drug Administration approved The complaint states that "West Virginia's Department of Health and Human Services has paid at least $70 million for It says studies have linked It alleges that sales representatives misled and deceived doctors about the safety and the efficacy of It alleges that advertisements deceptively understated risks and overstated benefits. It alleges that Lilly promoted "off label" prescriptions for anxiety, sleep disruption, mood swings, attention deficit hyperactivity and dementia. As a result of these actions, according to McGraw, Lilly sold more "Lilly benefited from its misrepresentations and fraudulent conduct by gaining sales of "The money paid ... ... "However beyond suggesting caution, our data provide no guidance on what treatments should be used to help manage the many conditions and symptoms that antipsychotics are used for - studies defining what optimal care is in the elderly are still sorely needed."
Email this article Join Our Forum and Write Your Opinion Print
RSS
Feed
This category only
Latest Articles
Mental Health Services Underutilized By Cancer Patients
Creative Strategies Improve Medical Care for Mentally Ill
Treatment of Down Syndrome in Mice Restores Nerve Growth in Cerebellum
Genetic Factors, Neuroticism May Be Associated with Future Development of Anorexia
Tips to Keep Your Mind in Top Shape
DIET & WEIGHT LOSS
FITNESS & EXERCISE
MEN'S HEALTH
WOMEN'S HEALTH
BEAUTY
ALTERNATIVE MEDICINE
CANCER TREATMENT
AGIN...... but I do think it has rebalanced the scales back toward a more sensible footing, so that people don't think that branded pharma is just going to lose every patent they've got."Investors across the European drugs sector took heart from the Plavix news on Wednesday, with GlaxoSmithKline Plc (GSK.L: Quote, Profile, Research) and AstraZeneca Plc (AZN.L: Quote, Profile, Research) climbing around 2 percent, while Sanofi itself surged nearly 10 percent.Sav Neophytou, a research analyst at stockbroker Seymour Pierce, said the deal was a "significant positive" for the sector and showed branded drug firms were finding ways to deal with generic threats.NOT RISK-FREESanofi and Bristol-Myers are following an increasingly well-trodden path in settling with Canada's Apotex Corp and attempting a similar accommodation with Dr Reddy's Laboratories Ltd (REDY.BO: Quote, Profile, Research) of India.In the past six months, numerous branded firms have reached similar deals, including Wyeth (WYE.N: Quote, Profile, Research), Cephalon Inc (CEPH.O: Quote, Profile, Research), Johnson & Johnson (JNJ.N: Quote, Profile, Research), Shire Plc (SHP.L: Quote, Profile, Research) and Allergan Inc (AGN.N: Quote, Profile, Research). Continued ... © Reuters 2006. All Rights Reserved. 1 | 2 Next
More Reuters Recom... 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | All news
|